{"id":"https://openalex.org/W2590575196","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7528","title":"Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients.","display_name":"Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2590575196","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7528","mag":"2590575196"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.7528","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7528","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.7528","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044795397","display_name":"Barbara Jennifer Gitlitz","orcid":"https://orcid.org/0009-0001-0107-3135","observed_orcids":["https://orcid.org/0009-0001-0107-3135"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. J. Gitlitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008285027","display_name":"Eric D. Bernstein","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. D. Bernstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018462109","display_name":"George P. Keogh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. P. Keogh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058967910","display_name":"Edgardo S. Santos","orcid":"https://orcid.org/0000-0003-0776-4903","observed_orcids":["https://orcid.org/0000-0003-0776-4903"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. S. Santos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004712121","display_name":"Gregory A. Otterson","orcid":"https://orcid.org/0000-0001-9877-8512","observed_orcids":["https://orcid.org/0000-0001-9877-8512"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. A. Otterson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"G. Milne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Milne","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003919741","display_name":"Mary Syto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Syto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5071468635","display_name":"Sara L. Zaknoen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. L. Zaknoen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"7528","last_page":"7528"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9262999892234802,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9262999892234802,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.05220000073313713,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.008200000040233135,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9750000238418579},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9929999709129333},{"id":"https://openalex.org/keywords/cox-2-inhibition","display_name":"COX-2 inhibition","score":0.8840000033378601},{"id":"https://openalex.org/keywords/urinary-biomarkers","display_name":"urinary biomarkers","score":0.8130000233650208},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7440000176429749},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.9440000057220459},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.8029999732971191},{"id":"https://openalex.org/keywords/age-subgroup-analysis","display_name":"age subgroup analysis","score":0.4189999997615814},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9319999814033508},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.527999997138977},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.7699999809265137},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.5170000195503235},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5070000290870667},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.3709999918937683}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9358812570571899},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7152354121208191},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6907169818878174},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6893260478973389},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6600465774536133},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.580936074256897},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5662829875946045},{"id":"https://openalex.org/C2777482430","wikidata":"https://www.wikidata.org/wiki/Q7168709","display_name":"Peripheral edema","level":3,"score":0.5602355003356934},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5345375537872314},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5081851482391357},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.48192715644836426},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.45500680804252625},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.41179999709129333},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.33976879715919495},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.29045405983924866},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27283304929733276},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.08716419339179993},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.07790639996528625},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.7528","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7528","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.7528","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2018251393","https://openalex.org/W2092145449","https://openalex.org/W2130163382","https://openalex.org/W2599218749","https://openalex.org/W1604183045","https://openalex.org/W1582428656","https://openalex.org/W2128905862","https://openalex.org/W2131228625","https://openalex.org/W418387390","https://openalex.org/W2966644526"],"abstract_inverted_index":{"7528":[0],"Background:":[1],"Apricoxib":[2],"is":[3,242,269,313],"a":[4,13,25,39,56,86,93,120,142,153,211,251,255],"selective":[5],"inhibitor":[6],"of":[7,43,98,148,179,259,266],"COX-2.":[8],"The":[9,45,116],"COX-2":[10,61],"pathway":[11],"plays":[12],"key":[14],"role":[15],"in":[16,54,70,97,123,141,216,235,254,302],"tumor":[17],"growth,":[18],"angiogenesis":[19],"and":[20,30,37,111,136,171,189,293],"resistance":[21],"to":[22,34,72,125,201,225,249,283],"therapy.":[23],"In":[24,206],"phase":[26,47,65,309],"I":[27],"trial":[28,67,248,312],"apricoxib":[29,99],"erlotinib":[31,106],"were":[32,100,103,139,223,295],"found":[33],"be":[35],"safe":[36],"demonstrated":[38,230],"disease":[40],"control":[41],"rate":[42],"60%.":[44],"recommended":[46],"II":[48,66],"dose":[49],"was":[50,119],"based":[51,209],"on":[52,194,210,275],"decreases":[53,69],"PGE-M;":[55],"urinary":[57,263],"marker":[58],"for":[59,75],"tumoral":[60],"activity.":[62],"Thus,":[63],"this":[64,267],"used":[68],"PGE-M":[71,91],"select":[73],"pts":[74,133,215,261,271,303],"randomization.":[76],"Methods:":[77],"Pts":[78,102],"with":[79,105,298],"IIIB":[80],"or":[81,169,306],"IV":[82],"NSCLC":[83,260],"that":[84],"had":[85,150,164],"50%":[87,154],"decrease":[88],"from":[89],"baseline":[90],"after":[92],"5-day":[94],"open-label":[95],"run":[96],"randomized.":[101],"treated":[104],"150":[107],"mg":[108],"PO":[109,114],"daily":[110],"apricoxib/placebo":[112],"400mg":[113],"daily.":[115],"primary":[117],"objective":[118],"40%":[121],"improvement":[122],"time":[124],"progression":[126],"over":[127],"the":[128,195,217,226,243,299],"placebo":[129,246],"arm.":[130],"Results:":[131],"176":[132],"entered":[134],"run-in":[135],"120/176":[137],"(68%)":[138],"randomized":[140,224,245],"2:1":[143],"(active:":[144],"placebo)":[145],"fashion":[146],"(82%":[147],"patients":[149,193],"at":[151],"least":[152],"drop).":[155],"Gender:":[156],"M/F:":[157],"67/53;":[158],"age":[159,220],"range":[160],"36-87":[161],"yrs.;":[162],"95%":[163],"an":[165,207],"ECOG":[166],"PS":[167],"0":[168],"1":[170],"5%,":[172],"PS2.":[173],"Most":[174],"common":[175],"adverse":[176],"events":[177],"(AEs)":[178],"any":[180],"grade":[181],"included;":[182],"diarrhea":[183],"(55%),":[184],"rash":[185],"(54%),":[186],"fatigue":[187],"(38%)":[188],"nausea":[190],"(33%).":[191],"More":[192],"active":[196,227,276,300],"combination":[197,228,268,301],"arm":[198,229],"discontinued":[199],"due":[200,282],"AEs":[202],"(7%":[203],"vs":[204,327,331,338,342,353,357],"21%).":[205],"analysis":[208],"pre-specified":[212],"subgroup":[213],"those":[214],"\u2264":[218,322],"65":[219,273,305,323],"group":[221],"who":[222],"statistically":[231],"significant":[232],"clinical":[233,252],"benefit":[234,253],"all":[236],"efficacy":[237],"measures.":[238],"Conclusions:":[239],"This":[240],"study":[241,280],"first":[244],"controlled":[247],"demonstrate":[250],"biomarker":[256],"selected":[257],"population":[258],"using":[262],"PGE-M.":[264],"Safety":[265],"acceptable,":[270],">":[272],"years":[274],"drug":[277],"experienced":[278],"more":[279],"discontinuations":[281],"AEs.":[284],"Although":[285],"overall":[286],"ITT":[287,315],"showed":[288],"no":[289],"benefit,":[290],"DCR,":[291],"TTP":[292,335],"OS":[294,350],"significantly":[296],"improved":[297],"aged":[304],"younger.":[307],"A":[308],"III":[310],"definitive":[311],"planned.":[314],"N=114":[316],"P":[317,320],"value":[318,321],"N=65":[319],"HR":[324,345,360],"DCR":[325],"46%":[326],"51%":[328],"NS":[329],"35%":[330],"60%":[332],"0.018":[333,344],"Median":[334,349],"(months)":[336,351],"2.1":[337],"1.8":[339],"0.97":[340],"1.4":[341],"2.7":[343],"0.5":[346],"(NA,":[347,362],"0.9)":[348,363],"5.6":[352],"5.9":[354],"0.83":[355],"3.8":[356],"8.5":[358],"0.025":[359],"0.4":[361]},"counts_by_year":[{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-03T00:00:00"}